Yahoo Finance 
Inhalation Anesthetics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
The global inhalation anesthetics market is estimated to be USD 1,223. 08 million in 2021. It is expected to reach USD 1,580. 98 million by 2027, registering a CAGR of 4. 46% from 2022 to 2027.
New York, April 27, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Inhalation Anesthetics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" - https://www.reportlinker.com/p06271839/?utm_source=GNW
The application of inhalation anesthetics for the diagnosis and treatment of COVID-19 and associated diseases has positively impacted the growth of the market. Volatile agents are effective in patients who need complex and high sedation, with significant reduction or removal of intravenous sedatives. Volatile agents contain mild muscle relaxation properties and may lower the usage of paralytic agents and benefit the lungs.
For instance, the article entitled “Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS” published in June 2020, states that isoflurane offers the highest potency with low dosing requirements for ICU patients. And these Volatiles are delivered to the patients through either an anesthesia machine or ICU ventilator with an in-line miniature vaporizer. These mini vaporizers are used to block the inhalation of carbon dioxide. And the article concluded that delivery of inhaled volatile sedation regimens with a good sedation profile may have benefits in the lung while easing pressure on essential sedative medications.
The market is expected to grow due to the increase in the number of surgeries being performed, globally. For instance, The Centre of Disease Control and Prevention (CDC) data updated in March 2022 related to Emergency Department Visits in United States shows that, in the year 2018, 130 million emergency hospital visits and number of injury-related visits were 35 million. This number increased from the prior year. In 2020, employers reported 2.7 million injury and illness cases in private industry. Injury cases declined to 2.1 million in 2020 from 2.7 million in 2019, while illness cases more than quadrupled to 544,600 cases in 2020, shows the United States Bureau Of Labor Statistics data. These surge in emergency cases and related increase in surgical interventions are one of the few factors, which is estimated to drive the growth of the studied market.
The factors, such as increasing adoption rate of minimally invasive surgeries, are also helping the market growth due to their effectiveness in a lesser hospitalization period. Minimally invasive surgeries have been reported to cause less post-operative pain. Hence, the patients receive smaller dosages of pain killers. Additionally, as there are minimal cuts or stitches involved, the hospital stay is relatively shorter, and the patients need not visit the hospital frequently. “Robotic Cardiac Surgery in Europe: Status 2020”, a study published in January 2022, concluded that, 2,563 procedures were carried out during a 4-year period (2016–2019) including robotically assisted coronary bypass grafting, the perioperative rates of revision for bleeding, stroke, and mortality were 2.2%, 0.2%, and 1.1%, respectively. And concluded that , the number of centers performing robotic cardiac surgery increased substantially.
However, side effects associated with the inhalation anesthetics, the lower adoption rate in case of inhaled anesthetics in certain surgical procedures, generic competition for almost all of the halogenated agents, and recent patent expiries are restraining the inhalation anesthetics market.
Key Market Trends
Sevoflurane Holds the Major Share in the Inhalation Anesthetics Market And Expected to do Same in the Forecast Period
Sevoflurane is the most widely used inhalation anesthetic, owing to its therapeutic advantages and low cost. Sevoflurane is an ether inhalation anesthetic agent with low pungency, a nonirritant odor, and a low blood, gas partition coefficient.
Sevoflurane is useful in adults and children for both induction and maintenance of anesthesia in inpatient and outpatient surgery. It is ideal for asthma patients or people with sensitized air passages. The drug can be administered without the use of an intravenous route. Sevoflurane is also used as an anesthetic gas for children, as it can be breathed in by a face mask and works very quickly in getting children off to sleep.
Factors, such as proven safety records of sevoflurane, increasing use for both out-patient and in-patient, increasing use for both human and veterinary healthcare, growing trends of cosmetic surgery and plastic surgery, and increasing incidences of orthopedic, onco-surgeries, and spinal surgeries, are propelling the growth of sevoflurane. The segment is also benefitting from an increase in accidents and emergency cases. These drugs are given to patients before surgery to make induction of general anesthesia substantially easier.
Moreover, it has been observed that there is a significant focus on researching the combination of sevoflurane with other anesthesia drugs to enhance the efficacy of the anesthesia in patients during surgical procedures.
As per the press release by International Institute for Integrative Sleep Medicine in February 2022, the researchers at the University of Tsukuba investigated the effect of the general anesthetic sevolurine and said that sevoflurane can improve sleep alteration in response to inflammation. In January 2022, Dechra Pharmaceuticals had announced the acquisition of Isoflurane USP Inhalant Anesthetic and Sevoflurane USP Inhalant Anesthetic from Halocarbon Life Sciences. These 2 inhalation anesthesia solutions are used in both human and animal medicine. Thus, due to the aforementioned factors, the overall market for Sevoflurane will grow steadily over the forecast period of the study.
North America Holds Major Share and Expected to do Same in the Forecast Period
Increased government funds for R&D of innovative inhalation anesthetic, as well as a rise in cancer incidences, are driving the overall growth of the North American inhalation anesthesia market. Furthermore, the market growth is fueled by an increase in the prevalence of diseases and surgical procedures performed for disease treatment and development. According to statistics published by the Government of Canada, released in November 2021, an estimated 229,200 Canadians will be diagnosed with cancer, and 84,600 will die from cancer every year. Lung, breast, colorectal, and prostate cancers are expected to remain the most diagnosed cancers, accounting for 46% of all diagnoses in 2021. According to their survey, breast cancer affects one out of every eight women at some point in their life. As the number of incidences of cancer increases, so does the urge to treat cancer with surgeries such as minimally invasive and open surgery, thus, driving demand for inhalation anesthetics over the forecast period.
In June 2020, Piramal Urgent Care (PCC) established a strategic partnership with Medivant Healthcare, a US-based pharmaceutical outsourcing facility, to help hospitals throughout the country solve the critical shortage of injectable drugs. In January 2019, Sandoz, a Novartis division, has launched Desflurance Liquid for inhalation. It is the first generic version of Suprane to be released in the United States. In patients undergoing inpatient and outpatient surgery, this liquid is utilized as an inhalation agent to maintain and induce anesthesia. Therefore, rising incidences of chronic diseases and growing company activities will significantly drive the market in the regional market during the study period.
Competitive Landscape
Market players in the inhalation anesthetics market are focusing on the expansion of their product portfolios by adopting inorganic growth strategies, such as acquisitions, mergers, and partnerships. The key market players that hold significant shares in the inhalation anesthetics market include Abbvie Inc., Baxter, Piramal Enterprises Ltd, and Hikma Pharmaceuticals PLC among others.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
Read the full report: https://www.reportlinker.com/p06271839/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
